Attilio Di Girolamo, Marcello Albanesi, Alessandro Sinisi, Eustachio Nettis, Danilo Di Bona, Maria Filomena Caiaffa, Luigi Macchia
{"title":"brentuximab vedotin (Adceteris®)过敏的快速脱敏1例报告。","authors":"Attilio Di Girolamo, Marcello Albanesi, Alessandro Sinisi, Eustachio Nettis, Danilo Di Bona, Maria Filomena Caiaffa, Luigi Macchia","doi":"10.1186/s12948-018-0100-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Brentuximab vedotin (BV) is an antibody-drug conjugate formed by an anti-CD30 chimeric IgG<sub>1</sub> conjugated with monomethyl-auristatin-E. BV targets the CD30<sup>+</sup> cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphoma. Once bound to the CD30<sup>+</sup> cells BV exerts its cytotoxic effect via the monomethyl-auristatin-E moiety. So far, accounts on immediate adverse reactions to BV remain anecdotal. Moreover, few reports exist on desensitization for BV.</p><p><strong>Case presentation: </strong>A 20-year old male patient was diagnosed with Hodgkin lymphoma in July 2014. The first line treatment with adriblastine, bleomicine, vinblastine and dacarbazine lead to a partial remission. Thus, a treatment with BV was started. However, during the second BV infusion, he developed generalized urticaria and dyspnea. In order not to discontinue the treatment with BV, we performed a thorough allergological workup and designed a 12-step rapid desensitization protocol. Overall the desensitization procedure was well tolerated and no major adverse reactions occurred.</p><p><strong>Conclusion: </strong>Rapid desensitization is a suitable and safe option in the case of BV allergy and prevents the BV treatment withdrawal.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"16 ","pages":"22"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-018-0100-0","citationCount":"6","resultStr":"{\"title\":\"Rapid desensitization for brentuximab vedotin (Adceteris<sup>®</sup>) allergy: a case report.\",\"authors\":\"Attilio Di Girolamo, Marcello Albanesi, Alessandro Sinisi, Eustachio Nettis, Danilo Di Bona, Maria Filomena Caiaffa, Luigi Macchia\",\"doi\":\"10.1186/s12948-018-0100-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Brentuximab vedotin (BV) is an antibody-drug conjugate formed by an anti-CD30 chimeric IgG<sub>1</sub> conjugated with monomethyl-auristatin-E. BV targets the CD30<sup>+</sup> cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphoma. Once bound to the CD30<sup>+</sup> cells BV exerts its cytotoxic effect via the monomethyl-auristatin-E moiety. So far, accounts on immediate adverse reactions to BV remain anecdotal. Moreover, few reports exist on desensitization for BV.</p><p><strong>Case presentation: </strong>A 20-year old male patient was diagnosed with Hodgkin lymphoma in July 2014. The first line treatment with adriblastine, bleomicine, vinblastine and dacarbazine lead to a partial remission. Thus, a treatment with BV was started. However, during the second BV infusion, he developed generalized urticaria and dyspnea. In order not to discontinue the treatment with BV, we performed a thorough allergological workup and designed a 12-step rapid desensitization protocol. Overall the desensitization procedure was well tolerated and no major adverse reactions occurred.</p><p><strong>Conclusion: </strong>Rapid desensitization is a suitable and safe option in the case of BV allergy and prevents the BV treatment withdrawal.</p>\",\"PeriodicalId\":38753,\"journal\":{\"name\":\"Clinical and Molecular Allergy\",\"volume\":\"16 \",\"pages\":\"22\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/s12948-018-0100-0\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Molecular Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12948-018-0100-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12948-018-0100-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: a case report.
Background: Brentuximab vedotin (BV) is an antibody-drug conjugate formed by an anti-CD30 chimeric IgG1 conjugated with monomethyl-auristatin-E. BV targets the CD30+ cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphoma. Once bound to the CD30+ cells BV exerts its cytotoxic effect via the monomethyl-auristatin-E moiety. So far, accounts on immediate adverse reactions to BV remain anecdotal. Moreover, few reports exist on desensitization for BV.
Case presentation: A 20-year old male patient was diagnosed with Hodgkin lymphoma in July 2014. The first line treatment with adriblastine, bleomicine, vinblastine and dacarbazine lead to a partial remission. Thus, a treatment with BV was started. However, during the second BV infusion, he developed generalized urticaria and dyspnea. In order not to discontinue the treatment with BV, we performed a thorough allergological workup and designed a 12-step rapid desensitization protocol. Overall the desensitization procedure was well tolerated and no major adverse reactions occurred.
Conclusion: Rapid desensitization is a suitable and safe option in the case of BV allergy and prevents the BV treatment withdrawal.
期刊介绍：
Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable. At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
